Construction of a Prognostic Immune-Related LncRNA Risk Model for Lung Adenocarcinoma

por Li, Yue, Shen, Ruoyi, Wang, Anqi, Zhao, Jian, Zhou, Jieqi, Zhang, Weijie, Zhang, Ruochen, Zhu, Jianjie, Liu, Zeyi, Huang, Jian-an
Publicado 2021

The regulation of CPNE1 ubiquitination by the NEDD4L is involved in the pathogenesis of non-small cell lung cancer

por Zhang, Ruochen, Zhang, Weijie, Zeng, Yuanyuan, Li, Yue, Zhou, Jieqi, Zhang, Yang, Wang, Anqi, Lv, Yantian, Zhu, Jianjie, Liu, Zeyi, Huang, Jian-an
Publicado 2021

CPNE1 promotes non-small cell lung cancer progression by interacting with RACK1 via the MET signaling pathway

por Wang, Anqi, Yang, Wen, Li, Yue, Zhang, Yang, Zhou, Jieqi, Zhang, Ruochen, Zhang, Weijie, Zhu, Jianjie, Zeng, Yuanyuan, Liu, Zeyi, Huang, Jian-an
Publicado 2022

EVI5 is an oncogene that regulates the proliferation and metastasis of NSCLC cells

por Cai, Tingting, Zhou, Jieqi, Zeng, Yuanyuan, Du, Wenwen, Zhang, Yang, Liu, Ting, Fu, Yulong, Huang, Jian-an, Qian, Qian, Zhu, Jianjie, Ling, Chunhua, Liu, Zeyi
Publicado 2020

ALCAP2 inhibits lung adenocarcinoma cell proliferation, migration and invasion via the ubiquitination of β-catenin by upregulating the E3 ligase NEDD4L

por Zhang, Weijie, Zhang, Ruochen, Zeng, Yuanyuan, Li, Yue, Chen, Yikun, Zhou, Jieqi, Zhang, Yang, Wang, Anqi, Zhu, Jianjie, Liu, Zeyi, Yan, Zhaowei, Huang, Jian-an
Publicado 2021

Integrin α3/α6 and αV are implicated in ADAM15-activated FAK and EGFR signalling pathway individually and promote non-small-cell lung cancer progression

por Zhou, Jieqi, Wang, Anqi, Cai, Tingting, Li, Yue, Du, Wenwen, Zhang, Yang, Zhang, Ruochen, Zhang, Weijie, Zhu, Jianjie, Zeng, Yuanyuan, Huang, Jian-an, Liu, Zeyi
Publicado 2022

CD151 drives cancer progression depending on integrin α3β1 through EGFR signaling in non-small cell lung cancer

por Zhu, Jianjie, Cai, Tingting, Zhou, Jieqi, Du, Wenwen, Zeng, Yuanyuan, Liu, Ting, Fu, Yulong, Li, Yue, Qian, Qian, Yang, Xiuwei H., Li, Qinglin, Huang, Jian-an, Liu, Zeyi
Publicado 2021

Corrigendum: Advanced NSCLC patients with EGFR T790M harbouring TP53 R273C or KRAS G12V cannot benefit from osimertinib based on a clinical multicentre study by tissue and liquid b...

por Fu, Yulong, Wang, Anqi, Zhou, Jieqi, Feng, Wei, Shi, Minhua, Xu, Xiao, Zhao, Hongqing, Cai, Liming, Feng, Jian, Lv, Xuedong, Zhang, Xiaodong, Xu, Wenjing, Zhang, Zhengrong, Ma, Guoer, Wang, Jian, Zhou, Tong, Zhao, Dahai, Fang, Haohui, Liu, Zeyi, Huang, Jian-an
Publicado 2023

Advanced NSCLC Patients With EGFR T790M Harboring TP53 R273C or KRAS G12V Cannot Benefit From Osimertinib Based on a Clinical Multicentre Study by Tissue and Liquid Biopsy

por Fu, Yulong, Wang, Anqi, Zhou, Jieqi, Feng, Wei, Shi, Minhua, Xu, Xiao, Zhao, Hongqing, Cai, Liming, Feng, Jian, Lv, Xuedong, Zhang, Xiaodong, Xu, Wenjing, Zhang, Zhengrong, Ma, Guoer, Wang, Jian, Zhou, Tong, Zhao, Dahai, Fang, Haohui, Liu, Zeyi, Huang, Jian-an
Publicado 2021